Thiol isomerase inhibitors and uses thereof

Extracellular thiol isomerase inhibitors like zafirlukast and montelukast address the limitations of current tools by blocking enzymes involved in thrombosis and cancer, providing effective treatments for thrombotic diseases and cancer through inhibition of enzymes like PDI, ERp5, and ERp57.

JP2024161023AInactive Publication Date: 2024-11-15WESTERN NEW ENGLAND UNIVERSITY
View PDF 1 Cites 0 Cited by

Patent Information

Application Number
JP2024134797
Authority / Receiving Office
JP · JP
Patent Type
Applications
Current Assignee / Owner
Priority Date
2017-01-30
Filing Date
2024-08-13
Publication Date
2024-11-15
Estimated Expiration
Not applicable · inactive patent

AI Technical Summary

Technical Problem

Current tools for studying thiol isomerases, such as antibodies, have limitations, and there is a need for pharmaceuticals like small molecules to target these enzymes for antithrombotic therapy and cancer treatment, as they are involved in thrombus formation, cancer tumorigenesis, and other disease processes.

Method used

Administration of extracellular thiol isomerase inhibitor compounds, including zafirlukast, montelukast, CGP-13501, and others, to inhibit enzymes like PDI, ERp5, ERp57, and ERp72, targeting conditions such as thrombosis, cancer, and infectious diseases.

Benefits of technology

These inhibitors effectively block platelet aggregation, thrombus formation, and cancer cell proliferation, offering potential therapeutic benefits in treating thrombotic diseases, cancer, and infectious conditions.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 2024161023000001_ABST
    Figure 2024161023000001_ABST
Patent Text Reader

Abstract

To provide pharmaceuticals for treating extracellular thiol isomerase-associated cancer and other disease-related processes.SOLUTION: Disclosed herein is a method for treating or preventing a disease or condition associated with the activity of one or more extracellular thiol isomerases (e.g., a protein disulfide isomerase, ERp5, ERp57, ERp72 and thioredoxin), comprising administering to a patient in need thereof a therapeutically effective amount of an inhibition compound of extracellular thiol isomerase. The disease or condition includes arterial thrombosis, venous thrombosis, a thrombotic disease, a cancer, an infectious disease, a viral disease, an immune disorder, inflammation, a neurologic disease, and a neurodegenerative disorder.SELECTED DRAWING: Figure 1
Need to check novelty before this filing date? Find Prior Art

Description

[Background technology]

[0001] Thiol isomerases are members of a large family of disulfide oxidoreductases that catalyze the post-translational disulfide exchange required for the proper folding of newly synthesized proteins. Approximately 20 members of the large thiol isomerase / disulfide oxidoreductase family are present in humans, and the domain composition of thiol isomerases is a-b'-a'. These thiol isomerases are generally capable of oxidation-reduction and isomerization reactions and are often found in the endoplasmic reticulum, where they catalyze the proper folding of newly translated proteins.

[0002] In addition, some thiol isomerases, such as protein disulfide isomerase (PDI), ERp5, ERp57, ERp72 and thioredoxin (TRX), have recently been found to perform extracellular functions. These five thiol isomerases, hereafter referred to as extracellular thiol isomerases, are secreted by cells such as platelets and reattach to the plasma membrane, where they function as extracellular oxidoreductases. Extracellular thiol isomerases have also been identified on the surface of endothelial cells, and have been identified to play a role in platelet aggregation, granule secretion, fibrinogen binding, and calcium mobilization, in addition to activating thrombus formation and fibrin formation. Of these enzymes, the role of PDI in thrombus formation is the most well studied and understood, but it is also known that ERp5, ERp57 and ERp72 are required.

[0003] The tools for studying thiol isomerases mainly include antibodies, which have limitations. There remains a need in the art for pharmaceuticals, such as small molecules, against these thiol isomerases that would provide a novel approach to antithrombotic therapy.

[0004] In addition, PDI family members are upregulated in many distinct cancer types, including ovarian, prostate, lung, melanoma, lymphoma, and glioma, while inhibition of PDI is cytotoxic in ovarian cancer cell lines. These enzymes are believed to have multifunctional involvement in cancer tumorigenesis, playing roles in oncogene activation, evasion of apoptosis, secretion of major histocompatibility complex class I-related A protein (MICA), and resistance to chemotherapeutic agents.

[0005] Moreover, there remains a need in the art for pharmaceutical agents, such as small molecules, directed against extracellular thiol isomerases to treat cancer and other disease-related processes in which these thiol isomerases are involved.

[0006] There is also a need in the art for the development of pharmaceutical agents that selectively and broadly target extracellular thiol isomerase to prevent and treat the onset or progression of diseases and conditions in which extracellular thiol isomerase is involved. Summary of the Invention

[0007] Disclosed herein are methods comprising administering a therapeutically effective amount of an extracellular thiol isomerase inhibitor compound to a patient in need thereof to treat or prevent a disease or condition affected by the activity of one or more extracellular thiol isomerases, wherein the extracellular thiol isomerase inhibitor compound is zafirlukast, montelukast, CGP-13501, CGP-7930, alosetron, balsalazide, benserazide, butaclamol, levadopa, mesalazine, oxcarbazepine, pharmaceutically acceptable salts, prodrugs, and / or solid state forms thereof.

[0008] In another embodiment, a method for preventing or treating thrombosis, thrombotic disorders, platelet aggregation, fibrin generation, or a combination thereof in a patient comprises administering a therapeutically effective amount of zafirlukast to a patient in need thereof.

[0009] In yet another embodiment, a method for inhibiting thiol isomerase of extracellular thiol isomerase in a cell comprises contacting the cell with an effective amount of zafirlukast, montelukast, CGP-13501, CGP-7930, alosetron, balsalazide, benserazide, butaclamol, levadopa, mesalazine, oxcarbazepine, pharmaceutically acceptable salts, prodrugs, and / or solid state forms thereof.

[0010] These and other features are illustrated in the drawings and detailed description that follow.

[0011] In general, the present disclosure may optionally comprise, consist of, or consist essentially of any suitable components disclosed herein. The present disclosure may further, or alternatively, be formulated to be devoid or substantially free of any components, materials, ingredients, adjuvants, or species used in prior art compositions or that are not otherwise necessary for the accomplishment of the function and / or purpose of the present disclosure.

[0012] Reference will now be made to the drawings, which are illustrative embodiments and are not to be considered limiting. [Brief description of the drawings]

[0013] [Figure 1] FIG. 1 shows data on the inhibition of various thiol isomerases by zafirlukast in in vitro enzyme assays. [Diagram 2] FIG. 1 shows data on the inhibition of various thiol isomerases by montelukast in in vitro enzyme assays. [Diagram 3] FIG. 1 shows data on the inhibition of various ERp57 by various concentrations of other inhibitors in an in vitro enzyme assay. [Figure 4] FIG. 1 shows data for inhibition of collagen-stimulated platelet aggregation by zafirlukast. [Diagram 5]FIG. 1 shows the maximum fluorescence intensity of thrombi formed in mice in the presence of zafirlukast (squares) or vehicle (circles). [Figure 6] FIG. 1 shows the effect of zafirlukast on bleeding time assessed by tail bleeding assay. DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

[0014] Disclosed herein are thiol isomerase inhibitors and their therapeutic use in preventing or treating the onset or progression of diseases or conditions in which one or more extracellular thiol isomerases are involved.

[0015] In one embodiment, a method for inhibiting one or more extracellular thiol isomerases in a patient in need thereof for the treatment or prevention of a disease or condition affected by the activity of one or more extracellular thiol isomerases, or for inhibiting a process affected by the activity of one or more extracellular thiol isomerases, comprises administering to the patient a therapeutically effective amount of an extracellular thiol isomerase inhibitor compound or a composition comprising an extracellular thiol isomerase inhibitor compound as disclosed herein. In certain embodiments, the disease or condition is thrombosis, a thrombotic disease, an infectious disease such as human immunodeficiency virus (HIV), cancer, inflammation, or a combination thereof, as described herein.

[0016] Extracellular thiol isomerase As used herein, "extracellular thiol isomerase" includes at least protein disulfide isomerase (PDI), thioredoxin (TRX), and the following endoplasmic reticulum-resident proteins: ERp5, ERp57, and ERp72.

[0017] PDI is a 508 amino acid protein that plays a key role in platelet activation. Release of PDI from activated platelets was demonstrated nearly 20 years ago and has been confirmed in many subsequent studies, and it is also released by endothelial cells. Antibodies against PDI and the antibiotic bacitracin at micromolar concentrations inhibit platelet aggregation, adhesion, and secretion. Inhibition of PDI has been shown to inhibit cancer cell proliferation and induce tumor necrosis in ovarian cancer models.

[0018] ERp5 is a 440 amino acid protein that contains two thioredoxin (CGHC-containing motif) domains and shares 47% sequence identity with PDI. Blockade of cell surface ERp5 results in decreased platelet aggregation, fibrinogen binding, and alpha granule secretion. In addition to its role in hemostasis, high levels of ERp5 expression have been shown to correlate with prevention of efficient antitumor responses in Hodgkin's lymphoma and have been proposed as a biomarker for prostate and breast cancer progression.

[0019] ERp57 is a 505 amino acid thiol isomerase that plays a key role in regulating early platelet activation and supporting arterial thrombus formation, affecting platelet aggregation, dense granule secretion, fibrinogen binding, calcium mobilization and thrombus formation under arterial blood flow conditions. In addition to its role in thrombus formation, ERp57 has also been shown to be required for proper folding of influenza hemagglutinin and to be involved in Alzheimer's disease progression and cancer metastasis.

[0020] ERp72 is a 645 amino acid soluble ER protein that shares 37% sequence homology with PDI. ERp72 has three catalytic CGHC domains, compared to two found in PDI, ERp5, and ERp57. The increase in the percentage of ERp72 attracted to the platelet surface after activation is higher than that of PDI, ERp5, and ERp57, suggesting that ERp72 plays an important, but currently unknown, role in platelet activation. The effect of ERp72 inhibition on thrombus formation is similarly unknown. In addition to its relocation to the activated platelet surface, ERp72 is involved in the polyomavirus infection process and also in NADPH oxidase (Nox)1 redox signaling.

[0021] In one embodiment, the target for inhibition is one or more thiol isomerases of extracellular thiol isomerases, such as protein disulfide isomerase (PDI), thioredoxin (TRX), ERp5, ERp57, and ERp72. In one embodiment, the target for inhibition is PDI. In one embodiment, the target for inhibition is thioredoxin (TRX). In one embodiment, the target for inhibition is ERp5. In one embodiment, the target for inhibition is ERp57. In one embodiment, the target for inhibition is ERp72.

[0022] The term "patient" as used herein is a human or non-human animal in need of medical treatment. Medical treatment can include treatment of an existing condition, such as a disease or disorder, preventative or prophylactic treatment, or diagnostic treatment. In some embodiments, the patient is a human patient.

[0023] The term "provide" as used herein means to give, administer, sell, distribute, give away (for profit or not), manufacture, compound, or distribute.

[0024] The term "providing an extracellular thiol isomerase inhibitor compound or a pharma- ceutically acceptable salt thereof with at least one additional therapeutic agent" as used herein means that the extracellular thiol isomerase inhibitor compound or a pharma- ceutically acceptable salt thereof and the additional active agent are provided simultaneously in a single dosage form, concomitantly in separate dosage forms, or administered in separate dosage forms for administration separated by some time within a time period such that both the extracellular thiol isomerase inhibitor compound or a pharma- ceutically acceptable salt thereof and the at least one additional active agent are present in the patient's bloodstream. The extracellular thiol isomerase inhibitor compound or a pharma- ceutically acceptable salt thereof and the additional active agent do not need to be prescribed to the patient by the same medical practitioner. The one or more additional active agents do not require a prescription. The administration of the extracellular thiol isomerase inhibitor compound or a pharma- ceutically acceptable salt thereof or the at least one additional active agent can be via any suitable route, such as oral tablet, oral capsule, oral liquid, inhalation, injection, suppository, or topical contact.

[0025] The term "treatment" as used herein includes providing an extracellular thiol isomerase inhibitor compound or a pharma- ceutically acceptable salt thereof, as the sole active agent or together with at least one additional active agent, sufficient to (a) prevent a disease or condition or a symptom of a disease or condition from occurring in a patient who may be susceptible to the disease or condition but has not yet been diagnosed as having it; (b) inhibit the disease or condition, i.e., arrest its onset; and (c) alleviate the disease or condition, i.e., cause the regression of the disease or condition. "Treat" and "treatment" also mean providing a therapeutically effective amount of an extracellular thiol isomerase inhibitor compound or a pharma- ceutically acceptable salt thereof, as the sole active agent or together with at least one additional active agent, to a patient suffering from a disease or condition affected by the activity of one or more extracellular thiol isomerases. "Disease or condition affected by the activity of one or more extracellular thiol isomerases" means that one or more extracellular thiol isomerases are involved in the disease or condition.

[0026] The extracellular thiol isomerase inhibitor compounds or pharmaceutical compositions / combinations disclosed herein are useful for treating patients. The extracellular thiol isomerase inhibitor compounds or pharmaceutical compositions / combinations are useful for treating or preventing diseases and disorders involving the activity of one or more extracellular thiol isomerases. In certain embodiments, the patient suffers from or is at risk of developing thrombosis. In certain embodiments, the patient suffers from cancer. In certain embodiments, the disease is blood cancer, HPV-related cancer, ovarian cancer, prostate cancer, gastric cancer, breast cancer, or colon (colorectal) cancer. In other embodiments, the patient to be treated suffers from an inflammatory disorder, an infectious disease, an immune disorder, or a neurological disease.

[0027] Extracellular thiol isomerase inhibitor compounds As used herein, "extracellular thiol isomerase inhibitor compound" is an inhibitor of one or more extracellular thiol isomerases.Exemplary extracellular thiol isomerase inhibitor compounds include zafirlukast, montelukast, CGP-13501 (CAS Registry Number 56189-68-5), CGP-7930 (CAS Registry Number 57717-80-3), alosetron, balsalazide, benserazide, butaclamol, levadopa, mesalazine, oxcarbazepine, their pharmaceutically acceptable salts, prodrugs, and / or solid state forms.As an inhibitor of one or more extracellular thiol isomerases, one or more of these compounds can be used as antithrombotic agents, and anticoagulants, antiinflammatory agents, antiviral agents, chemotherapeutic agents or anticancer agents, etc., or combinations thereof.

[0028] Zafirlukast is a synthetic selective peptide leukotriene receptor antagonist (LTRA) with the chemical name 4-(5-cyclopentyloxycarbonylamino-l-methylindol-3-ylmethyl)-3-methoxy-No-tolylsulfonylbenzamide. We have discovered that zafirlukast is a broad-spectrum thiol isomerase inhibitor that inhibits platelet function, thrombus formation, and cancer cell proliferation.

[0029] [ka]

[0030] The synthesis and pharmaceutical forms of zafirlukast are further described in U.S. Pat. Nos. 4,859,692; 5,294,636; 5,319,097; 5,482,963; 5,583,152; 5,612,367; 6,143,775; 6,333,361; and 6,399,104, the contents of which are incorporated herein by reference in their entireties.

[0031] Montelukast is a synthetic peptide leukotriene receptor antagonist (LTRA) with the chemical name [R-(E)]-l-[[[l-[3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(7-chloro-2-quinolinyl)ethenyl]phenyl]-3-[2-(1-hydroxy-1-methylethyl)phenyl]propyl]thio]methylcyclopropaneacetic acid. The synthesis and pharmaceutical forms of montelukast and montelukast sodium are further described in U.S. Pat. No. 5,565,473, which is incorporated herein by reference in its entirety.

[0032] The term "active agent" as used herein means a compound (such as an extracellular thiol isomerase inhibitor compound), component, or mixture that, when administered to a patient alone or in combination with another compound, component, or mixture, directly or indirectly confers a physiological effect on the patient. The indirect physiological effect may occur via a metabolite or other indirect mechanism. When the active agent is a compound, salts, solvates (such as hydrates) of the free compound, crystalline forms of the compound, non-crystalline (i.e., amorphous) forms, and any polymorphs are included. All forms are contemplated herein, regardless of the method used to obtain them.

[0033] The term "pharmaceutically acceptable salts" as used herein includes derivatives of the disclosed compounds, where the parent compound is modified by preparing its inorganic and organic acid or base addition salts. The salts of the compounds of the present invention can be synthesized from the parent compound containing a basic or acidic moiety by conventional chemical methods. In general, such salts can be prepared by reacting the free acid forms of these compounds with a stoichiometric amount of a suitable base (e.g., hydroxides, carbonates, or bicarbonates of Na, Ca, Mg, or K, etc.), or by reacting the free base forms of these compounds with a stoichiometric amount of a suitable acid. Such reactions are typically carried out in water or in an organic solvent, or in a mixture of the two. When applicable, non-aqueous media such as ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are generally used. The salts of the compounds of the present invention further include solvates of the compounds and salts of the compounds.

[0034] Examples of pharma- ceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic residues such as amines; alkali or organic salts of acidic residues such as carboxylic acids; and the like. Pharmaceutically acceptable salts include, for example, conventional non-toxic salts of the parent compound formed from non-toxic inorganic or organic acids, and quaternary ammonium salts. For example, conventional non-toxic acid salts include those derived from inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, sulfamic acid, phosphoric acid, nitric acid, and the like; and those derived from acetic acid, propionic acid, succinic acid, glycolic acid, stearic acid, lactic acid, malic acid, tartaric acid, citric acid, ascorbic acid, pamoic acid, maleic acid, hydroxymaleic acid, phenylacetic acid, glutamic acid, benzoic acid, salicylic acid, mesylic acid, esylic acid, besylic acid, sulfanilic acid, 2-acetoxybenzoic acid, fumaric acid, toluenesulfonic acid, methanesulfonic acid, ethanedisulfonic acid, oxalic acid, isethionic acid, HOOC-(CH2) nand salts prepared from organic acids such as -COOH, where n is 0 to 4. Lists of additional suitable salts can be found, for example, in Remington's Pharmaceutical Sciences, 17th ed., Mack Publishing Company, Easton, Pa., p. 1418 (1985).

[0035] antithrombotic Extracellular thiol isomerases are involved in the regulation of hemostasis and thrombosis, since inhibition of one or more extracellular thiol isomerases blocks platelet aggregation, granule secretion, adhesion, thrombus formation and fibrin production. Antithrombotic agents can be used therapeutically for the prevention (primary prevention, secondary prevention) or treatment of dangerous blood clots (acute thrombosis).

[0036] Inhibition of PDI, ERp5 or ERp57 activity blocks thrombus formation following laser-induced injury of blood vessels in a mouse model of thrombosis.

[0037] Moreover, because inhibition of thiol isomerase activity has effects on both platelet accumulation and fibrin formation, these treatments represent an improvement over currently available therapies that only target either arterial clots (heart attacks and strokes largely triggered by inappropriate activation of platelets) or venous clots (deep vein thrombosis and pulmonary embolism largely caused by inappropriate activation of the coagulation system).The data suggest that each thiol isomerase has unique substrate specificity and mechanism of action, suggesting that each may be an independent target.

[0038] The thrombotic disease or condition prevented or treated by the extracellular thiol isomerase inhibitor compounds can be acute myocardial infarction, stable angina, unstable angina, acute occlusion following coronary angioplasty and / or stent placement, transient ischemic attack, cerebrovascular disease, stroke, peripheral vascular disease, placental insufficiency, atrial fibrillation, deep vein thrombosis, pulmonary embolism, or a combination thereof.

[0039] Platelet responses in the presence of zafirlukast (0.1 μM to 10 μM) were tested in a wide range of platelet function assays, including aggregation, granule secretion and spreading studies. Zafirlukast was found to inhibit platelet aggregation, dense and α-granule secretion, platelet spreading on collagen and clot formation under flow. These data suggest that zafirlukast and other broad-spectrum inhibitors of thiol isomerases of the protein disulfide isomerase subfamily may be used as antithrombotic agents.

[0040] In one embodiment, the disease or condition affected by the activity of one or more extracellular thiol isomerases is arterial thrombosis, venous thrombosis, thrombotic diseases, such as acute myocardial infarction, stable angina, unstable angina, acute occlusion after coronary angioplasty and / or stent placement, transient ischemic attack, cerebrovascular disease, stroke, peripheral vascular disease, placental insufficiency, atrial fibrillation, deep vein thrombosis, and pulmonary embolism, or a combination thereof, and the extracellular thiol isomerase inhibitor compound is zafirlukast.

[0041] Anti-cancer PDI inhibition is a viable target for cancer therapy. See Xu et al., "Protein disulfide isomerase: a promising target for cancer therapy," Drug Discovery Today, Vol. 19, No. 3, March 2014.

[0042] Further evidence exists for a role for ERp5 in tumor metastasis, see Gumireddy et al., "In vivo selection for metastasis promoting genes in the mouse," PNAS (2007) 104:6696-6701.

[0043] ERp57 is expressed from the PDIA3 gene in humans. It consists of 505 amino acids and is upregulated in melanomas as well as breast, lung, uterine, gastric and liver cancers compared to normal tissues. The expression level of ERp57 is positively correlated with the transforming ability of oncogenic sarcoma viruses in NIH3T3 cells, suggesting that ERp57 is involved in oncogenic transformation. Unlike other PDI family members, ERp57 interacts with DNA molecules through its catalytically active a' domain, so ERp57 has the ability to interact with nuclear DNA and activate gene expression. ERp57 is also a component of the STAT3 transcription complex, and ERp57-STAT3 modulates STAT3-regulated cell signaling and proliferation. ERp57 also regulates gene expression through the mTOR pathway, another important regulator of cell proliferation and survival. ERp57 is also involved in binding to at least three proteins involved in DNA repair, such as Ref-l / APE, which itself has the ability to activate additional transcription factors. In addition to its gene regulatory function, increased ERp57 expression correlates with resistance to treatment with paclitaxel in ovarian cancer and radioresistance in laryngeal cancer, promotes breast cancer metastasis to bone, and is involved in deregulation of EGFR signaling in breast cancer cell lines, preventing its downstream activation of target molecules such as STAT3, Akt, and PLCy. ERp57 plays a role in thrombus formation and is therefore a potential target for the prevention of cancer-associated thrombosis, a major cause of morbidity and mortality in cancer patients.

[0044] The cancer treated with the extracellular thiol isomerase inhibitor compound can be ovarian cancer, prostate cancer, lung cancer, melanoma, lymphoma, glioma, breast cancer, or neuroblastoma.

[0045] The extracellular thiol isomerase inhibitor compounds may be used alone or, optionally, in combination with another anti-cancer or chemotherapeutic agent.

[0046] In one embodiment, cancer is treated with a combination of an extracellular thiol isomerase inhibitor compound and a chemotherapeutic agent such as carboplatin or cisplatin. In such an embodiment, the extracellular thiol isomerase inhibitor compound may provide an advantage by overcoming or preventing carboplatin and / or cisplatin resistance.

[0047] Anti-infectious / Anti-viral Thiol isomerases, particularly PDI, are also involved in HIV-1 entry. The use of broad spectrum thiol isomerase inhibitors (e.g., zafirlukast) can confer a protective effect and prevent viral entry, as demonstrated by Khan et al., "Discovery of a Small Molecule PDI Inhibitor That Inhibits Reduction of HIV-1 Envelope Glycoprotein gpl20.", ACS Chemical Biology, Vol. 6, No. 3, March 2011.

[0048] The viral disease treated or prevented using the extracellular thiol isomerase inhibitor compound may be HIV, dengue virus, or rotavirus. The extracellular thiol isomerase inhibitor compound or compounds may further be used to treat or prevent infectious diseases such as cholera, as demonstrated by Orlandi. "Protein Disulfide Isomerase-mediated Reduction of the A Subunit of Cholera Toxin in a Human Intestinal Cell Line." The Journal of Biochemistry, Vol. 272, No. 7, February 14, 2007.

[0049] anti-inflammatory The inflammation treated with the extracellular thiol isomerase inhibitor compounds can be inflammation of the lungs, joints, connective tissue, eyes, nose, intestine, kidneys, liver, skin, central nervous system, vasculature or heart. PDIs have been demonstrated to play an essential role in the attraction of neutrophils and activation of innate immune responses during vascular inflammation and tissue injury.

[0050] Neurological and neurodegenerative disorders Thiol isomerase is present in the brain and is upregulated in patients with neurological folding disorders such as Creutzfeldt-Jakob disease, Alzheimer's disease, Huntington's disease, and Parkinson's disease. The use of broad spectrum thiol isomerase inhibitors (e.g., zafirlukast) may confer protective effects to prevent or reduce neurological degeneration, treat neurodegenerative disorders, and treat neurological diseases and disorders due to increased reactive oxygen species damage and apoptosis associated with PDI subfamily members in neurodegenerative diseases. Previous studies have demonstrated that PDI inhibitors can suppress toxicity associated with misfolded Huntington and b-amyloid proteins.

[0051] Pharmaceutical Compositions, Dosages One or more extracellular thiol isomerase inhibitor compounds can be administered as pure chemicals or as pharmaceutical compositions.Thus, the embodiments provide pharmaceutical compositions comprising an extracellular thiol isomerase inhibitor compound or a pharma- ceutically acceptable salt thereof together with a pharma- ceutically acceptable carrier.The pharmaceutical composition may contain an extracellular thiol isomerase inhibitor compound or a pharma- ceutically acceptable salt thereof as the only active agent, or may contain one or more additional active agents.

[0052] The extracellular thiol isomerase inhibitor compound may be administered orally, topically, parenterally, by inhalation or spray, sublingually, transdermally, via buccal administration, rectally, as eye drops, or by other means in a dosage form containing a conventional pharma- ceutically acceptable carrier.The pharmaceutical composition may be formulated in any pharma- ceutically useful form, for example, as an aerosol, cream, gel, pill, capsule, tablet, syrup, transdermal patch, or eye drops.Some dosage forms, such as tablets and capsules, may be further divided into suitably metered unit doses containing an appropriate amount of active ingredient, for example, an effective amount to achieve the desired purpose.

[0053] The term "dosage form" as used herein means a unit of administration of an active agent. Examples of dosage forms include tablets, capsules, injections, suspensions, liquids, emulsions, creams, ointments, suppositories, inhalable forms, transdermal forms, etc. An exemplary dosage form is a solid oral dosage form.

[0054] The term "pharmaceutical composition" as used herein is a composition that contains at least one active agent, such as a compound or salt of formula I, and at least one other substance, such as a carrier. The pharmaceutical composition meets the US FDA GMP (Good Manufacturing Practice) standards for human or non-human drugs. The pharmaceutical composition can be formulated into a dosage form.

[0055] The term "carrier" as used herein applied to pharmaceutical compositions refers to a diluent, excipient, or vehicle with which an active compound is provided.

[0056] Carriers include excipients and diluents, and must be sufficiently pure and sufficiently low toxic so as to be suitable for administration to the patient being treated.Carriers may be inert or may have pharmaceutical benefits of their own.The amount of carrier used in combination with the compound is sufficient to provide a practical amount of material for administration per unit dose of the extracellular thiol isomerase inhibitor compound.

[0057] Carrier classes include, for example, buffers, coloring agents, diluents, disintegrants, emulsifiers, flavorings, glidants, lubricants, preservatives, stabilizers, surfactants, tableting agents, and wetting agents.Some carriers may be listed in more than one class, for example, vegetable oils may be used as lubricants in some formulations and as diluents in other formulations.Exemplary pharma-ceutically acceptable carriers include sugar, starch, cellulose, powdered tragacanth, malt, gelatin, talc, and vegetable oils.Optional active agents that do not substantially interfere with the activity of the extracellular thiol isomerase inhibitor compound may be included in the pharmaceutical composition.

[0058] The pharmaceutical compositions may be formulated for oral administration. These compositions contain 0.1 to 99 weight percent ("wt %), specifically at least about 5 wt %, of the extracellular thiol isomerase inhibitor compound. In some embodiments, the compositions contain about 25 wt % to about 50 wt % or about 5 wt % to about 75 wt % of the extracellular thiol isomerase inhibitor compound.

[0059] The term "therapeutically effective amount" of a pharmaceutical composition, as used herein, refers to an amount that, when administered to a patient, is effective to provide a therapeutic benefit, such as prevention or amelioration of symptoms, for example, to treat a patient suffering from a disease or condition affected by the activity of one or more extracellular thiol isomerases. The therapeutically effective amount may vary according to factors such as the condition, age, and weight of the patient, and the ability of the compound to induce a desired response in the patient. Dosage regimens may be adjusted to provide optimal therapeutic success. A therapeutically effective amount is also an amount in which any toxic or deleterious effects (e.g., side effects) of the inhibitor compound are outweighed by the therapeutically beneficial effects.

[0060] The therapeutically effective amount may be within the range of about 0.001 μg / kg / day to about 500 mg / kg / day, preferably 0.01 μg / kg / day and 100 mg / kg / day. Those skilled in the art will appreciate that certain factors may affect the dosage required to effectively treat a patient, including, but not limited to, the severity of the disease or disorder, previous treatments, the patient's general health and / or age, and other diseases present. Furthermore, treatment of a patient with a therapeutically effective amount of an inhibitor compound may include a single treatment or may include a series of treatments. It will also be understood that the effective dosage of an inhibitor compound used for treatment may increase or decrease over the course of a particular treatment.

[0061] The extracellular thiol isomerase inhibitor compound can be administered to a patient in need thereof once, twice, or three times daily. In this embodiment, administration can be orally.

[0062] When administered orally, the total daily dose of zafirlukast, its pharma- ceutically acceptable salts, prodrugs, and / or solid state forms can be about 10 to about 200 mg, specifically about 20 to about 175 mg, more specifically about 40 to about 150 mg, and even more specifically about 60 to about 125 mg, which may be administered orally once, twice, or three times daily.

[0063] The pharmaceutical composition can be formulated in a package that includes the pharmaceutical composition in a container and further includes instructions for using the composition in the prevention and treatment of a disease or disorder mediated by one or more of the extracellular thiol isomerases.

[0064] This invention is further illustrated by the following examples which should not be construed as limiting. EXAMPLES

[0065] Example 1. Insulin-based turbidimetric assay - Assay for thiol isomerase inhibitory activity Recombinant thiol isomerase was purchased from AbCam (Cambridge MA), recombinant insulin (bovine), bacitracin, dithiothreitol (DTT) buffer and all other chemicals were purchased from Sigma Aldrich (St. Louis, MO), and 384-well clear bottom plates were purchased from Corning (Corning, NY).

[0066] Catalytic reduction of insulin by thiol isomerase in the presence of DTT results in aggregation of insulin chains. The turbidity of insulin aggregation can be monitored spectrophotometrically at optical density (OD) at 650 nm. This approach has been used by numerous groups to identify thiol isomerase inhibitors in a kinetic or end-point manner. Final concentrations of either 10 μg / mL PDI, 30 μg / mL ERp5, 10 μg / mL ERp72 or 10 μg / mL thioredoxin, 125 μM insulin and 2 mM ethylenediaminetetraacetic acid (EDTA) in 30 μL of 100 mM potassium phosphate buffer were added to each experimental well plate, and no thiol isomerase was added to negative control wells. Lead compounds were diluted in a 6-point dose curve and the turbidity of insulin aggregation was measured kinetically for 75 minutes each using a Spectramax M3 plate reader (Molecular Devices, Sunnyvale, CA.). The specificity assay also utilized an insulin turbidity assay.

[0067] Figure 1 shows the results of an assay for thiol isomerase inhibitory activity of zafirlukast. Zafirlukast was found to be a broadly applicable inhibitor of PDI, ERp5, ERp57, ERp72, and thioredoxin (TRX) enzymes. Zafirlukast was found to have an inhibitory range of 10-300 μM for ERp5, PDI is inhibited at 30-300 μM, TRX is inhibited within the range of 10-300 μM, ERp57 is inhibited at 30-300 μM, and ERp72 is inhibited at 10-300 μM.

[0068] FIG. 2 shows the results of an assay of the thiol isomerase inhibitory activity of montelukast.

[0069] Figure 3 shows data on inhibition of ERp57 by various concentrations of the inhibitors oxcarbazepine, benserazide, CGP-7930, and alosetron in an in vitro enzyme assay. It was further found that CGP-13501 is specific for ERp57.

[0070] Example 2. Studies demonstrating that zafirlukast is a thiol isomerase inhibitor capable of inhibiting platelet function Because zafirlukast and montelukast are broadly active inhibitors of the extracellular thiol isomerase thiol isomerase (see Example 1), a decrease in the overall platelet response is expected when platelets are treated with the compounds.

[0071] Materials: Zafirlukast and montelukast were purchased from Sigma Aldrich (Poole, UK). Collagen was obtained from Takeda (Linz, Austria). Chronolume and ATP for dense granule secretion experiments were purchased from Chronolog (Pennsylvania, USA). Anti-human P-selectin (CD62P) and anti-human PAC-1 antibodies were obtained from BD Biosciences (New Jersey, USA), and anti-human fibrinogen FITC conjugate was obtained from Dako Cytochemicals (Cambridgeshire, UK). CRP-XL was purchased from Prof Richard Farndale (University of Cambridge, UK). Microscope slides and cover slips were purchased from VWR (Pennsylvania USA). Prolong Anti Fade Gold Medium and Alexa-Fluor Phalloidin 488 were obtained from Thermo Fisher (California, USA). Cellix chips were obtained from Cellix (Dublin, Ireland). DioC6, thrombin, PGI2, DMSO, fibrinogen, protease-free bovine serum albumin (BSA) and all other reagents were of analytical grade and obtained from Sigma Aldrich (Poole, UK).

[0072] Preparation of human platelets: 50 mL of blood was drawn from drug-free consenting individuals into a syringe containing 5 mL of sodium citrate (4% w / v) and 7.5 mL of warmed ACD (85 mM sodium citrate, 71 mM citric acid, and 110 mM glucose). The blood was centrifuged at 102 g for 20 min to obtain platelet-rich plasma (PRP), which was then decanted and 10 μL of prostacyclin (PGI2 125 μg / mL, dissolved in ethanol) was added. Platelets were pelleted by centrifugation at 1413 g for 10 min, platelet-poor plasma was discarded, and the pellet was resuspended in 25 mL of Tyrode's HEPES buffer (134 mM NaCl, 2.9 mM KCl, 0.34 mM Na2HP04, 12 mM NaHC03, 20 mM HEPES, 1 mM MgCl2, and 5 mM glucose, pH 7.3), 3 mL of ACD and 10 μL of PGI2 were added, followed by centrifugation at 1413 g for 10 min, and the platelet pellet was resuspended to the appropriate cell density using Tyrode's buffer. Platelets were left at 30° C. for 30 min to allow platelet responses to recover.

[0073] Platelet aggregation: (4×10 8 445 μL of washed platelets (cells / mL) were incubated with vehicle (0.1% (v / v) DMSO) or 5 μL of zafirlukast or montelukast for 5 min. 50 μL of collagen (1 μg / mL) (final) was added and light transmission was monitored for 3 min at 37°C with constant agitation (1200 rpm) using an aggregometer (Chronolog, USA).

[0074] Dense granule secretion: 395 μL of washed platelets were added to a cuvette and incubated with 5 μL of zafirlukast or vehicle (DMSO, 0.1% (v / v)) for 3 min at 37°C. 50 μL of Chronolume substrate was added and incubated for an additional 2 min. Platelets were then stimulated with 50 μL of collagen (1 μg / mL) for 3 min at 37°C with constant agitation (1200 rpm) in a Lumi-aggregometer (Model 700, Chronolog USA).

[0075] Clot formation under flow: Human blood was collected in 3.2% (w / v) sodium citrate and labeled with 2 μM DIOC-6 for 1 h. Cellix biochips were coated with 1 μL of collagen (100 μg / mL) for 1 h. Blood was then incubated with vehicle (0.1% (v / v) DMSO) or zafirlukast (10 μM) for 5 min before being transferred to a flow tube at 20 dynes / cm. 2 The collagen was perfused over a collagen-coated Cellix microfluidic cell at a shear rate of 100 nm. Images were recorded by confocal microscopy (Nikon Al Microscope, Nikon, Japan) over 10 min of perfusion and analyzed using Image J.

[0076] Flow cytometry: 5 μL of platelets (2 × 10 8 Platelets (cells / mL) were added to 42 μL of HEPES-buffered saline containing 1 mM Ca2+. To this was added 0.5 μL of zafirlukast (0.6 μM-10 μM) or montelukast (0.6 μM-10 μM) or vehicle (0.1% (v / v) DMSO) and incubated for 5 minutes. 1 μL of anti-human CD62p (1:500 dilution) and 1 μL of anti-fibrinogen FITC conjugate (1:500 dilution) or 2 μL of anti-PAC-1 antibody were added to the sample. Platelets were treated with 5 μL of CRP-XL (1 ug / mL) or 5 μL of Tyrode's for 20 minutes in the dark. Samples were then fixed with 450 μL of 0.2% (v / v) paraformaldehyde and analyzed on an accuri C6 flow cytometer (BD Biosciences, UK) with a threshold set at 20,000. The platelet population was gated and 10,000 events were recorded.

[0077] Statistical analysis: All raw data were analyzed by one-way ANOVA and normalized to vehicle where appropriate. Statistical analysis was performed by ANOVA or Student's T-test using GraphPad Prism. Significance levels of p-values ​​are as follows: *p<0.05, **p<0.01, ***p<0.005. Data presented are the mean ± standard error of the mean.

[0078] Zafirlukast inhibits platelet aggregation: In human washed platelets (4×l0 8 Cells (100 / mL) were pretreated with 0.1 μM to 10 μM zafirlukast or vehicle. Platelets were stimulated with 1 μg / mL collagen and allowed to aggregate for 3 min. Representative aggregation traces of the response were obtained and dose responses were compared.

[0079] Data from 12 donors were normalized to vehicle and statistical significance was calculated using one-way ANOVA versus vehicle control. Zafirlukast was found to inhibit collagen-stimulated platelet aggregation in a concentration-dependent manner (Figure 4). Zafirlukast at 10 μM reduced platelet aggregation to 18.1% (± 5.62%, 81.9% inhibition) (p<0.0001). Zafirlukast at 5 μM and 2.5 μM inhibited platelet aggregation by 22.47% ± 6.2% and 40.00% ± 10.03% (77.53% and 60% inhibition, respectively) (p<0.0001). Similar intermediate levels of aggregation were detected at concentrations of 1.25 μM and 0.6 μM. Aggregation was 54.9% (±11.38%) and 54.8% (±11.07%), therefore 1.25 μM and 0.6 μM had similar inhibition of 45%. (p<0.01). 0.3 μM and 0.1 μM did not significantly inhibit platelet aggregation. Montelukast was also found to inhibit collagen-stimulated platelet aggregation. 10 μM inhibited the aggregation response by 3.99 ± 0.800%, 96.1% inhibition (p<0.0001). 5 μM, 3.75 μM and 2.5 μM, which inhibited by 90.63% ± 3.14, 83.56% ± 10.35 and 62.13% ± 10.15, respectively, were all found to be statistically significant.

[0080] Zafirlukast inhibits dense granule secretion: the release of ATP and other molecules from dense granules contributes to a positive feedback mechanism, thus leading to the modification of integrin αIIbβ3 and further aggregation of platelets. Because platelet aggregation was disrupted by zafirlukast, the positive feedback effect of granule exocytosis may also be disrupted.

[0081] Washed platelets (4 × l0 8 Cells (1000 cells / mL) were pretreated with zafirlukast (0.1-10 μM) or vehicle for 3 min. Chronolume was added for an additional 2 min, after which platelets were stimulated with 1 μg / mL (final) collagen for 3 min in a lumi-aggregometer. Statistical analysis was calculated using one-way ANOVA (n=3) (*P<0.05). Zafirlukast inhibited ATP secretion at 10 μM with a mean ATP secretion of 0.327 nM (±0.0727 nM) compared to vehicle-secreted ATP (1.25 nM, ±0.34 nM) (P<0.05).

[0082] Zafirlukast inhibits fibrinogen binding to αIIbβ3: Upon platelet activation, the affinity of the fibrinogen receptor αIIbβ3 for its ligand, fibrinogen, increases. This allows platelets to cross-link and thus thrombus initiation. PDI, ERp5 and ERp57 have all been shown to modulate fibrinogen binding through the use of function-blocking antibodies, pointing to a fundamental role for these enzymes in regulating the affinity of this receptor. Zafirlukast, a potential broadly available thiol isomerase inhibitor, may also inhibit fibrinogen binding by inhibition of granule secretion in a manner similar to enzyme activity-blocking antibodies.

[0083] The highest concentration of zafirlukast (10 μM) caused an inhibition of fibrinogen binding of 64.45% (±10.43%) (3696 Au ±1159 Au) (p<0.05) compared to vehicle (12520 Au, ±3264). A trend towards inhibition was observed with lower concentrations of zafirlukast.

[0084] Zafirlukast inhibits integrin activation: following second messenger-induced calcium release, integrin αIIbβ3 changes conformation to form an active state in which anti-human PAC-1 antibody can bind.

[0085] Washed platelets (2 × 10 8 Platelets (0.6–10 μM cells / mL) were incubated with vehicle, zafirlukast (0.6–10 μM) or montelukast (0.6–10 μM) for 5 min. After this, platelets were incubated with anti-PAC-1 antibody and stimulated with CRP-XL, after which the levels of cell surface-bound PAC-1 antibody were examined by flow cytometry. Data were analyzed using one-way ANOVA (n=3).

[0086] Zafirlukast inhibited integrin activation by 54% (±4.337%, 748.5 Au, ±87.46) at 10 μM compared to vehicle (1623 Au, ±34.67) (p<0.005).

[0087] Zafirlukast affects thrombus formation under flow: Thiol isomerases, particularly ERp57, have previously been shown to play an important role in platelet adhesion and thrombus formation under arterial flow. Using an in vitro thrombus formation model, we identified whether zafirlukast has any physiological effect on thrombi formed under flow conditions.

[0088] Human whole blood labeled with the lipophilic dye DIOC-6 was incubated with zafirlukast (10 μM) or vehicle (0.1% (v / v) DMSO) for 5 min and then stained at 20 dynes / cm 2Collagen (100 μg / mL) was perfused over a cellix capillary coated with collagen at an arterial shear rate of 100 μg / mL. Images were recorded for 10 min using confocal microscopy and analyzed using Image J. Median fluorescence intensity was determined and compared to the maximum intensity response. The higher the fluorescence, the larger the volume of the thrombus formed.

[0089] For both vehicle- and zafirlukast-treated blood, the median fluorescence and therefore the size of the clot increased with increasing time. After 8 min of flow, blood treated with 10 μM zafirlukast showed a slight decrease in median fluorescence intensity and therefore clot formation (p<0.05), with the MFI decreasing to 74.86 (±3.371 Au) compared to vehicle at 89.15 (±1.679 Au). The final size of the clot was also significantly decreased compared to vehicle (p<0.05; two-way ANOVA, three donors). Zafirlukast inhibited the median fluorescence intensity by 14.25% compared to vehicle. Therefore, it is concluded that zafirlukast reduces clot formation in whole blood under arterial flow conditions.

[0090] These results support the conclusion that zafirlukast inhibits platelet aggregation, granule secretion, integrin activation, and thrombus formation under flow, possibly through thiol isomerase mediation. These data support the potential of zafirlukast as a thiol isomerase inhibitor and an inhibitor of platelet functional responses.

[0091] Example 3. Zafirlukast inhibits thrombus formation in mice in vivo but does not affect bleeding The effect of zafirlukast on thrombus formation in mice was determined after laser injury of the cremaster arteriole and observed by intravital microscopy. Platelets from male C57 / BL6 mice were labeled with DyLight 649-conjugated anti-GPIb antibody (0.2 μg / g body weight) and either vehicle or zafirlukast (ZFL) (volume required to achieve a circulating concentration of 20 μM) were injected. After laser injury, images were recorded for 5 min. Figure 5 shows the maximum fluorescence intensity of each thrombus formed in vehicle-treated mice (n=18 thrombi, circles) or ZFL-treated mice (n=12 thrombi, squares), demonstrating that treatment with ZFL results in a reduction in thrombus size. Figure 6 shows that the effect of ZFL on hemorrhage was determined by tail bleeding assay. Vehicle or ZFL (volume required to achieve a circulating concentration of 20 μM) was injected into the femoral vein of C57 / BL6 mice, and tail biopsies were performed 5 min later. 0.5 cm of the tail tip was excised, blood was collected in phosphate buffered saline (PBS) and the time to cessation of bleeding was recorded. Treatment with ZFL was not associated with changes in bleeding time. Graphs represent the mean ± SEM of n=10 per treatment and data were analyzed by Student's T test (***p<0.005).

[0092] Example 4. Effect of extracellular thiol isomerase inhibitors on cancer cell proliferation Cells were plated at 6,000 cells / well in 96-well plates and treated after 24 hours with the indicated concentrations of zafirlukast. Cells were grown for an additional 24 hours, after which changes in proliferation were measured in triplicate by PrestoBlue cell proliferation assay. Fluorescence readings were collected using excitation at 570 nm and emission at 600 nm, and treated samples were converted to a percentage of untreated controls.

[0093] OVCar8 (human ovarian cancer cell line), HCTl16 (human colon cancer), HeLa (cervical cancer cell line) and MDA-MB-231 (breast cancer cell line) cell lines were examined for their ability to inhibit cell proliferation. OVCar8 and HCTl16 cells exhibited IC50s in the range of 5-10 μM. The HeLa cervical cancer cell line and the MDA-MB-231 breast cancer line were less sensitive. Table 1 shows the results of the cell proliferation assay in which zafirlukast was tested against OVCar8, HCTl16, HeLa and MDA-MB-231 cells.

[0094] [Table 1]

[0095] Example 5. Zafirlukast inhibits EGFR signaling HCT116 (human colon carcinoma) cells were incubated with the drugs for 24 hours and total cell extracts were prepared. Protein levels were normalized and proteins were run on SDS-polyacrylamide gels followed by electrophoresis and subsequent transfer to PVDF membranes. Membranes were probed with the primary antibody of interest followed by a secondary antibody conjugated to horseradish peroxidase. Western blots of HCT116 cells treated with zafirlukast showed near complete inhibition of EGFR activation and its downstream signaling, monitored through measurement of STAT3 phosphorylation.

[0096] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs.

[0097] The singular forms "a," "an," and "the" include plural referents unless the context clearly dictates otherwise. The endpoints of all ranges for the same feature or component are independently combinable and inclusive of the recited endpoints. As used herein, the suffix "(s)" is intended to include both the singular and the plural of the term it modifies, thereby including one or more of that term (e.g., carrier(s) includes one or more carriers). The term "or" means "and / or" unless the context clearly dictates otherwise. The term "combination" includes blends, mixtures, and the like.

[0098] References throughout this specification to "one embodiment," "another embodiment," "some embodiments," etc. mean that a particular component (e.g., a feature, structure, step, or characteristic) described in connection with that embodiment is included in at least one embodiment described herein and may or may not be present in other embodiments. In addition, it should be understood that the described components may be combined in any suitable manner in the various embodiments.

[0099] In general, the compositions, methods, and articles may optionally comprise, consist of, or consist essentially of any ingredient, step, or component disclosed herein. The compositions, methods, and articles may additionally, or alternatively, be formulated, performed, or manufactured to be devoid of, or substantially free of, any ingredient, step, or component that is not necessary for the accomplishment of the function or purpose of the claimed invention.

[0100] "Optional" or "optionally" means that the subsequently described event or circumstance may or may not occur, and that the description includes cases where the event occurs as well as cases where it does not occur.

[0101] As used herein, "about" or "approximately" means inclusive of the stated value and within an acceptable range of deviation for the particular value as determined by one of ordinary skill in the art taking into account the measurement in question and the error associated with measuring the particular quantity (e.g., limitations of the measurement system). For example, "about" can mean within one or more standard deviations.

[0102] Although the present invention has been described in detail in connection with only a limited number of embodiments, it should be readily understood that the present invention is not limited to such disclosed embodiments. Rather, the present invention may be modified to incorporate numerous variations, alterations, substitutions, or equivalent arrangements not described herein, but which are commensurate with the spirit and scope of the present invention. Furthermore, while various embodiments of the present invention have been described, it should be understood that aspects of the invention may include only some of the described embodiments. Thus, the present invention should not be viewed as limited by the foregoing description, but only by the appended claims.

[0103] All referenced patents, patent applications, and other references are incorporated herein by reference in their entirety, however, if a term in this application conflicts or conflicts with a term in the incorporated reference, the term from this application takes precedence over the inconsistent term from the incorporated reference.

Claims

1. A method comprising administering a therapeutically effective amount of an extracellular thiol isomerase inhibitor compound to a patient in need thereof to treat or prevent a disease or condition affected by the activity of one or more extracellular thiol isomerases, wherein the extracellular thiol isomerase inhibitor compound is zafirlukast, montelukast, alosetron, balsalazide, benserazide, butaclamol, levadopa, mesalazine, oxcarbazepine, pharmaceutically acceptable salts, prodrugs, and / or solid state forms thereof.

2. 2. The method of claim 1, wherein the one or more thiol isomerases of the extracellular thiol isomerase are protein disulfide isomerase (PDI), thioredoxin, ERp5, ERp57, ERp72, or a combination thereof.

3. The method of claim 1 or 2, wherein the extracellular thiol isomerase inhibitor compound is zafirlukast.

4. 4. The method of any one of claims 1 to 3, wherein the disease or condition is arterial thrombosis, venous thrombosis, a thrombotic disease, cancer, an infectious disease, a viral disease, an immune disorder, inflammation, a neurological disease, a neurodegenerative disorder, or a combination thereof.

5. The method of any one of claims 1 to 3, wherein the disease or condition is thrombosis or a thrombotic disease.

6. 6. The method of claim 5, wherein the thrombotic disease is acute myocardial infarction, stable angina, unstable angina, acute occlusion after coronary angioplasty and / or stent placement, transient ischemic attack, cerebrovascular disease, stroke, peripheral vascular disease, placental insufficiency, atrial fibrillation, deep vein thrombosis, pulmonary embolism, or a combination thereof.

7. The method of any one of claims 1 to 3, wherein the disease or condition is cancer.

8. 8. The method of claim 7, wherein the cancer is breast cancer, colon cancer, colorectal cancer, glioma, blood cancer, laryngeal cancer, lung cancer, lymphoma, melanoma, neuroblastoma, ovarian cancer, prostate cancer, or a combination thereof.

9. The method of any one of claims 1 to 8, wherein the extracellular thiol isomerase inhibitor compound is formulated as a pharmaceutical composition optionally further comprising a pharma- ceutically acceptable carrier.

10. The method of any one of claims 1 to 9, wherein the extracellular thiol isomerase inhibitor compound is formulated as a pharmaceutical composition in a dosage form.

11. The method of claim 10 , wherein the extracellular thiol isomerase inhibitor compound is formulated as a tablet or capsule.

12. The method of any one of claims 1 to 10, wherein the extracellular thiol isomerase inhibitor compound is formulated as a pharmaceutical composition suitable for administration orally, topically, parenterally, by inhalation or spray, sublingually, transdermally, via buccal administration, or rectally.

13. The method of any one of claims 1 to 12, further comprising providing said patient with at least one additional therapeutic agent.

14. 14. The method of claim 13, wherein the additional therapeutic agent is an antithrombotic agent, an anticoagulant agent, a chemotherapeutic agent, an antiviral agent, or an anti-inflammatory agent.

15. 1. A method for preventing or treating thrombosis, a thrombotic disorder, platelet aggregation, fibrin production, or a combination thereof in a patient, comprising: administering a therapeutically effective amount of zafirlukast to said patient in need thereof.

16. 16. The method according to claim 15 for the prevention or treatment of arterial and venous thrombosis.

17. 17. The method of claim 15 or 16, comprising administering a total daily dose of zafirlukast of about 10 to about 200 mg, specifically about 20 to about 175 mg, more specifically about 40 to about 150 mg, and even more specifically about 60 to about 125 mg, administered once, twice, or three times daily.

18. 1. A method for inhibiting an extracellular thiol isomerase in a cell, comprising: The method comprises contacting the cell with an effective amount of zafirlukast, montelukast, alosetron, balsalazide, benserazide, butaclamol, levadopa, mesalazine, oxcarbazepine, pharma- ceutically acceptable salts, prodrugs, and / or solid state forms thereof.

19. 19. The method of claim 18, wherein the thiol isomerase of the extracellular thiol isomerase is protein disulfide isomerase (PDI), thioredoxin, ERp5, ERp57, ERp72, or a combination thereof.

Citation Information

Patent Citations

  • Antitumor agent

    WO2014175253A1